While our macro view is bullish on small-cap biotech for 2006, we do not recommend indiscriminate buying.

The company came through with about 38% operating margins this quarter, guiding 42% over the next couple of year. That's dramatic translation of top-line revenues to the bottom line.

I'm not surprised. That's the Atlantic Coast Conference.

It affects the oxygen transportation system that occurs in the gills of fish.

We were outplayed, out-coached and thoroughly whipped by a very good North Carolina team. Our rebounding was basically non-existent, and I'm very disappointed in the way we played.

Sometimes when you turn the calendar to March, everybody gets a fresh breath.